Literature DB >> 22782690

Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinson's disease.

Megan K Young1, Shu-Kay Ng, George Mellick, Paul A Scuffham.   

Abstract

PURPOSE: The EuroQoL (EQ-5D) is ideal to compare quality of life across conditions. However, the Parkinson's Disease Questionnaire (PDQ-39) is often the only quality-of-life instrument used in Parkinson's disease research. We aimed to identify associations between PDQ-39 domains and EQ-5D domains, and compare different methods of developing a function to map the PDQ-39 to EQ-5D scores.
METHODS: Adults with Parkinson's disease self-completed both instruments. Ordinal regression identified associations between PDQ-39 domain scores and each EQ-5D domain. Modeling (n = 80) and validation sets (n = 16) were randomly generated. Overall performance of four methods of mapping the PDQ-39 to EQ-5D scores (using PDQ-39 domains and total score in ordinal and linear regression) was assessed with the validation set, followed by assessing the equivalence of observed and predicted EQ-5D scores on the full dataset controlling for sociodemographic factors.
RESULTS: Different sets of PDQ-39 domains were associated with each EQ-5D domain. For example, PDQ-39 "Activities of Daily Living" and "Social Support" were associated with EQ-5D "Personal Care," while PDQ-39 "Emotional Well-being" was associated with EQ-5D "Anxiety/Depression." Over one-third (37.5 %) of predictions from ordinal regressions had an error <0.01 % (compared to 6.3 % for linear regressions). The EQ-5D scores predicted with ordinal regression using PDQ-39 domains were similar in distribution and association with sociodemographic factors to the observed EQ-5D scores.
CONCLUSIONS: Of the four methods tested, using PDQ-39 domains in ordinal regression was superior for mapping EQ-5D scores. The function reported here may prove particularly useful for cost-utility analyses comparing Parkinson's disease with other conditions.

Entities:  

Mesh:

Year:  2012        PMID: 22782690     DOI: 10.1007/s11136-012-0231-6

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  28 in total

1.  Assessing proportionality in the proportional odds model for ordinal logistic regression.

Authors:  R Brant
Journal:  Biometrics       Date:  1990-12       Impact factor: 2.571

2.  Preference-Based EQ-5D index scores for chronic conditions in the United States.

Authors:  Patrick W Sullivan; Vahram Ghushchyan
Journal:  Med Decis Making       Date:  2006 Jul-Aug       Impact factor: 2.583

3.  Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample.

Authors:  Patrick W Sullivan; Vahram Ghushchyan
Journal:  Med Decis Making       Date:  2006 Jul-Aug       Impact factor: 2.583

4.  Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease.

Authors:  Francesc Valldeoriola; Ossama Morsi; Eduardo Tolosa; Jordi Rumià; Maria José Martí; Pablo Martínez-Martín
Journal:  Mov Disord       Date:  2007-11-15       Impact factor: 10.338

5.  PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures.

Authors:  V Peto; C Jenkinson; R Fitzpatrick
Journal:  J Neurol       Date:  1998-05       Impact factor: 4.849

6.  Coping processes and health-related quality of life in Parkinson's disease.

Authors:  R S Bucks; K E Cruise; T C Skinner; A M Loftus; R A Barker; M G Thomas
Journal:  Int J Geriatr Psychiatry       Date:  2010-07-13       Impact factor: 3.485

7.  The Parkinson's Disease Questionnaire (PDQ-39): evidence for a method of imputing missing data.

Authors:  Crispin Jenkinson; Catherine Heffernan; Helen Doll; Ray Fitzpatrick
Journal:  Age Ageing       Date:  2006-06-13       Impact factor: 10.668

8.  Health-related quality of life in multiple system atrophy.

Authors:  Anette Schrag; Felix Geser; Michaela Stampfer-Kountchev; Klaus Seppi; Martin Sawires; Martin Köllensperger; Christoph Scherfler; Niall Quinn; Maria T Pellecchia; Paolo Barone; Francesca Del Sorbo; Alberto Albanese; Karen Ostergaard; Erik Dupont; Adriana Cardozo; Eduardo Tolosa; Christer F Nilsson; Håkan Widner; Olle Lindvall; Nir Giladi; Tanya Gurevich; Christine Daniels; Günther Deuschl; Miguel Coelho; Cristina Sampaio; Michael Abele; Thomas Klockgether; Nicole Schimke; Karla M Eggert; Wolfgang Oertel; Ruth Djaldetti; Carlo Colosimo; Giuseppe Meco; Werner Poewe; Gregor K Wenning
Journal:  Mov Disord       Date:  2006-06       Impact factor: 10.338

9.  Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort study.

Authors:  Yaroslav Winter; Sonja von Campenhausen; Julia Gasser; Klaus Seppi; Jens-P Reese; Karl-P Pfeiffer; Kai Bötzel; Wolfgang H Oertel; Richard Dodel; Werner Poewe
Journal:  J Neurol       Date:  2009-11-28       Impact factor: 4.849

10.  Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden: an exploratory study.

Authors:  Ivar Sønbø Kristiansen; Kerstin Bingefors; Dag Nyholm; Dag Isacson
Journal:  Appl Health Econ Health Policy       Date:  2009       Impact factor: 2.561

View more
  7 in total

1.  Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.

Authors:  Gang Chen; Miguel A Garcia-Gordillo; Daniel Collado-Mateo; Borja Del Pozo-Cruz; José C Adsuar; José Manuel Cordero-Ferrera; José María Abellán-Perpiñán; Fernando Ignacio Sánchez-Martínez
Journal:  Patient       Date:  2018-12       Impact factor: 3.883

2.  The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration.

Authors:  Stavros Petrou; Oliver Rivero-Arias; Helen Dakin; Louise Longworth; Mark Oppe; Robert Froud; Alastair Gray
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

Review 3.  Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database.

Authors:  Helen Dakin
Journal:  Health Qual Life Outcomes       Date:  2013-09-05       Impact factor: 3.186

4.  Predicting health-related quality of life (EQ-5D-5 L) and capability wellbeing (ICECAP-A) in the context of opiate dependence using routine clinical outcome measures: CORE-OM, LDQ and TOP.

Authors:  Jasmine Peak; Ilias Goranitis; Ed Day; Alex Copello; Nick Freemantle; Emma Frew
Journal:  Health Qual Life Outcomes       Date:  2018-05-30       Impact factor: 3.186

5.  Impact of subthreshold depression on health-related quality of life in patients with Parkinson's disease based on cognitive status.

Authors:  Aline Schönenberg; Hannah M Zipprich; Ulrike Teschner; Julian Grosskreutz; Otto W Witte; Tino Prell
Journal:  Health Qual Life Outcomes       Date:  2021-03-25       Impact factor: 3.186

6.  Investigating the efficacy and safety of elobixibat, an ileal bile acid transporter inhibitor, in patients with Parkinson's disease with chronic constipation: a multicentre, placebo-controlled, randomised, double-blind, parallel-group stud (CONST-PD).

Authors:  Taku Hatano; Genko Oyama; Yasushi Shimo; Kotaro Ogaki; Noriko Nishikawa; Jiro Fukae; Ryota Nakamura; Naohide Kurita; Taiji Tsunemi; Yutaka Oji; Shinji Saiki; Kenya Nishioka; Haruka Takeshige-Amano; Daisuke Taniguchi; Takashi Ogawa; Hikaru Kamo; Hiroto Eguchi; Atsuhito Fuse; Asuka Nakajima; Masayoshi Kano; Sho Nakajima; Naotake Yanagisawa; Nobutaka Hattori
Journal:  BMJ Open       Date:  2022-02-11       Impact factor: 3.006

7.  An exercise intervention to prevent falls in Parkinson's: an economic evaluation.

Authors:  Emily Fletcher; Victoria A Goodwin; Suzanne H Richards; John L Campbell; Rod S Taylor
Journal:  BMC Health Serv Res       Date:  2012-11-23       Impact factor: 2.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.